Halozyme Therapeutics CEO Helen Torley's 2019 pay rises 1% to $5.9M
Halozyme Therapeutics reports 2019 executive compensation
By ExecPay News
Published: March 20, 2020
Halozyme Therapeutics reported fiscal year 2019 executive compensation information on March 20, 2020.
In 2019, five executives at Halozyme Therapeutics received on average a compensation package of $3M, which is about the same as previous year.
Average pay of disclosed executives at Halozyme Therapeutics
Helen I. Torley, Chief Executive Officer, received $5.9M in total, which increased by 1% compared to 2018. 37% of Torley's compensation, or $2.2M, was in stock awards. Torley also received $712K in non-equity incentive plan, $2.2M in option awards, $761K in salary, as well as $16K in other compensation.
For fiscal year 2019, the median employee pay was $238,096 at Halozyme Therapeutics. Therefore, the ratio of Helen I. Torley's pay to the median employee pay was 25 to one.
Alison Armour, Former Senior Vice President, Head of Research & Development, received a compensation package of $2.7M. 37% of the compensation package, or $1M, was in stock awards.
Laurie D. Stelzer, Chief Financial Officer, earned $2.2M in 2019, a 15% increase compared to previous year.
Benjamin J. Hickey, Former Senior Vice President, Chief Commercial Officer, received $2.2M in 2019, which decreases by 37% compared to 2018.
Harry J. Leonhardt, General Counsel, earned $1.9M in 2019, a 2% increase compared to previous year.
Related executives
Helen Torley
Halozyme Therapeutics
Chief Executive Officer
Laurie Stelzer
Halozyme Therapeutics
Chief Financial Officer
Harry Leonhardt
Halozyme Therapeutics
General Counsel
Alison Armour
Halozyme Therapeutics
Former Senior Vice President, Head of Research & Development
Benjamin Hickey
Halozyme Therapeutics
Former Senior Vice President, Chief Commercial Officer
You may also like
Source: SEC filing on March 20, 2020.